Summary
Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
Not applicable.
References
Somboonporn W, Davis SR, National H, Medical Research C. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev. 2004;25:374–88.
McDonnell DP, Wardell SE, Chang CY, Norris JD. Next-generation endocrine therapies for breast cancer. J Clin Oncol. 2021;39:1383–8.
Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Pushing estrogen receptor around in breast cancer. Endocr Relat Cancer. 2016;23:T227–T41.
Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003;10:292–8.
Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69:6131–40.
Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, et al. The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clin Cancer Res. 2018;24:2328–41.
Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000;14:1725–30.
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16:R7.
D’Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, et al. Cooperative dynamics of AR and ER activity in breast cancer. Mol Cancer Res. 2016;14:1054–67.
Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, et al. A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26:6149–57.
Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, et al. A phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer. Clin Cancer Res. 2017;23:4046–54.
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021;27:310–20.
Goldenberg IS. Testosterone propionate therapy in breast cancer. JAMA. 1964;188:1069–72.
Kennedy BJ. Fluoxymesterone therapy in advanced breast cancer. N Engl J Med. 1958;259:673–5.
Overmoyer B, Sanz-Altamira P, Taylor RP, Hancock ML, Dalton JT, Johnston MA, et al. Enobosarm: a targeted therapy for metastatic, androgen receptor positive, breast cancer. J Clin Oncol. 2014;32:568.
Caswell-Jin JL, Curtis C. Androgen receptor agonists as breast cancer therapeutics. Nat Med. 2021;27:198–9.
Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW. ARe we there yet? Understanding androgen receptor signaling in breast cancer. npj Breast Cancer. 2020;6:47.
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36:884–90.
Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, et al. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat. 2021;187:155–65.
Acknowledgements
None.
Author information
Authors and Affiliations
Contributions
TEH wrote the manuscript with critical discussions and editing from ARD and WDT.
Corresponding author
Ethics declarations
Funding
TEH is currently funded by a fellowship from the National Breast Cancer Foundation (IIRS-19-009). This work was supported by grants from the National Health and Medical Research Council of Australia (1130077; 1084416) and a joint Movember & National Breast Cancer Foundation Initiative Grant (MNBCF-17-012).
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
Not applicable.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hickey, T.E., Dwyer, A.R. & Tilley, W.D. Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer. Br J Cancer 125, 1599–1601 (2021). https://doi.org/10.1038/s41416-021-01478-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-021-01478-8